Public Release: 

Mechanism of fibrosis development discovered

Helmholtz Zentrum München - German Research Center for Environmental Health

IMAGE

IMAGE: These are extracellular vesicles under the electron microscope view more 

Credit: Helmholtz Zentrum München

Idiopathic pulmonary fibrosis (IPF) is an incurable lung disease of unknown origin with limited treatment options. Research suggests that the signaling molecule WNT5A plays a key role in the pathogenic process. Now a group of scientists from Helmholtz Zentrum München working with colleagues from the University of Denver have taken a further step towards uncovering the mechanisms responsible for the development of fibrosis: IPF is associated with the increase of extracellular vesicles that relay WNT5A signals to cells in the lungs. The study, published in the American Journal of Respiratory and Critical Care Medicine, proposes a further pharmacological biomarker and a possible therapeutic approach.

Pulmonary fibrosis is associated with the increased formation of connective tissue in the lungs, resulting in scarring (fibrosis) of functional lung tissue. This leads to a decrease in the inner surface of the extremely fine alveoli and the extensibility of the lungs, which, in turn, impedes the intake of oxygen and the release of carbon dioxide. The result is impaired lung function. IPF is a particularly aggressive form of the disease that cannot be attributed to a specific cause. The symptoms worsen rapidly. Existing drugs can slow progression of the disease but are unable to stop it permanently.

Research is therefore continuing to focus on elucidating the mechanisms underlying the pathological tissue changes associated with IPF. One approach that has been intensively pursued for several years now in the Department of Lung Repair and Regeneration (LRR) and the Institute of Lung Biology and Disease (ILBD) at Helmholtz Zentrum München aims to influence the so-called WNT signaling pathway. It is already known that the signaling molecule WNT5A is responsible for stimulating the proliferation of connective tissue cells in the lungs.

Vesicles transport scarring signals

The LRR Research Group headed by Dr. Dr. Melanie Königshoff has found that extracellular vesicles are very likely also involved in IPF. "Simply put, extracellular vesicles are tiny pouches released by cells that can contain a large number of messenger substances, such as proteins and nucleic acids," describes Dr. Mareike Lehmann, one of the authors of the study. "They are an important means of communication between cells and organs and help to ensure that the substances reach completely new sites."

Until recently, it was unclear whether and how extracellular vesicles are implicated in IPF. "We were able to show in the study that increased levels of extracellular vesicles occur in IPF patients, which then act as carriers of WNT5A," explains lead author Aina Martin-Medina. "We were also able to confirm these results in our experimental model." In addition, the authors showed in Petri dish experiments that reducing the number of vesicles decreases tissue scarring.

In further preclinical studies, the researchers now want to examine the suitability of extracellular vesicles as a pharmacological biomarker, as well as a possible therapeutic target.

###

Further Information

Original Publication:

Martin-Medina A. et al. (2018): Increased Extracellular Vesicles Mediate WNT-5A Signaling in Idiopathic Pulmonary Fibrosis. American journal of respiratory and critical care medicine 2018. DOI: 10.1164/rccm.201708-1580OC

The Helmholtz Zentrum München, the German Research Center for Environmental Health, pursues the goal of developing personalized medical approaches for the prevention and therapy of major common diseases such as diabetes, allergies and lung diseases. To achieve this, it investigates the interaction of genetics, environmental factors and lifestyle. The Helmholtz Zentrum München is headquartered in Neuherberg in the north of Munich and has about 2,300 staff members. It is a member of the Helmholtz Association, a community of 18 scientific-technical and medical-biological research centers with a total of about 37,000 staff members. http://www.helmholtz-muenchen.de/en

The Lung Repair and Regeneration Research Unit is part of the Comprehensive Pneumology Center (CPC), which is a joint undertaking of the Helmholtz Zentrum München, Ludwig Maximilian University Munich with its University Hospital, and the Asklepios Specialist Clinics Munich-Gauting. The CPC's objective is to conduct research on chronic lung diseases in order to develop new diagnostic tools and therapies. The LRR Research Unit examines new mechanisms and repair processes in the lungs for a better understanding that will allow the development of new therapeutic approaches. The unit also focuses on developing new methods in order to reduce the gap between pre-clinical research and its application on patients. The CPC is a facility of the German Center for Lung Research (Deutsches Zentrum für Lungenforschung - DZL). http://www.helmholtz-muenchen.de/lrr

Contact for the media:

Department of Communication, Helmholtz Zentrum München - German Research Center for Environmental Health, Ingolstädter Landstr. 1, 85764 Neuherberg - Tel. +49 89 3187 2238 - Fax: +49 89 3187 3324 - E-mail: presse@helmholtz-muenchen.de

Scientific contact:

Dr. Dr. Melanie Königshoff, Helmholtz Zentrum München - German Research Center for Environmental Health, Comprehensive Pneumology Center, Max-Lebsche-Platz 31, 81377 München, Germany - Tel. +49 89 3187 4668 - E-mail: melanie.koenigshoff@helmholtz-muenchen.de

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.